IPI Legacy Liquidation Co's revenue for the
three
months ended in Sep. 2023 was $5.02 Mil.
Its revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $20.99 Mil.
IPI Legacy Liquidation Co's Revenue per Share for the
three
months ended in Sep. 2023 was $0.21.
Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.88.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of IPI Legacy Liquidation Co's Revenue
For the Biotechnology subindustry, IPI Legacy Liquidation Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IPI Legacy Liquidation Co's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IPI Legacy Liquidation Co's Revenue distribution charts can be found below:
* The bar in red indicates where IPI Legacy Liquidation Co's Revenue falls into.
IPI Legacy Liquidation Co Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $20.99 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IPI Legacy Liquidation Co (OTCPK:IMPLQ) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
IPI Legacy Liquidation Co Revenue Related Terms
Thank you for viewing the detailed overview of IPI Legacy Liquidation Co's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
IPI Legacy Liquidation Co (IPI Legacy Liquidation Co) Business Description
Impel Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. The company is developing an approach to drug delivery that administers specific formulations of drugs deep into the vascular-rich upper nasal space, a gateway for therapeutic administration of a versatile range of molecules and formulations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IMPLQ has been successfully added to your 